-+ 0.00%
-+ 0.00%
-+ 0.00%

BRISTOL MYERS SQUIBB PRESENTS RESULTS FROM PHASE 1 BREAKFREE-2 STUDY OF ZOLACABTAGENE AUTOLEUCEL (BMS-986353) IN PATIENTS WITH HIGHLY ACTIVE RELAPSING AND PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS AT MSTORONTO 2026

Reuters·10/23/2026 14:31:07

Veuillez vous connecter pour afficher les détails des actualités